You can buy or sell ImmunoGen and other stocks, options, ETFs, and crypto commission-free!
ImmunoGen, Inc. Common Stock, also called ImmunoGen, is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Read More Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Immunogen Inc. Stock Quote (U.S.: Nasdaq)
Shares of Immunogen Inc. plummeted 48% toward a two-year low in premarket trade Friday, after the company said a phase 3 trial of its ovarian cancer treatment, mirvetuximab soravtansine, compared to chemotherapy, failed to meet its primary endpoint of progression free survival. The company said that based on the efficacy signals, overall response rate and survival, it will conduct additional analysis to evaluation the potential benefit of mirvetuximab soravtansine for FRα-positive platinum-resistant ovarian...
Yahoo FinanceMar 12
Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock
Investors in ImmunoGen, Inc. IMGN need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 3, 2019 $3.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could a...
Yahoo FinanceMar 10
ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. It has been about a month since the last earnings report for ImmunoGen (IMGN). Shares have lost about 50.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is ImmunoGen due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most ...
Expected May 3, Pre-Market